CY1120082T1 - Αμινογλυκοσιδες και χρησεις αυτων στη θεραπευτικη αγωγη γενετικων διαταραχων - Google Patents

Αμινογλυκοσιδες και χρησεις αυτων στη θεραπευτικη αγωγη γενετικων διαταραχων

Info

Publication number
CY1120082T1
CY1120082T1 CY20181100039T CY181100039T CY1120082T1 CY 1120082 T1 CY1120082 T1 CY 1120082T1 CY 20181100039 T CY20181100039 T CY 20181100039T CY 181100039 T CY181100039 T CY 181100039T CY 1120082 T1 CY1120082 T1 CY 1120082T1
Authority
CY
Cyprus
Prior art keywords
aminoglycosides
genetic disorders
therapeutic treatment
alkyl
group
Prior art date
Application number
CY20181100039T
Other languages
Greek (el)
English (en)
Inventor
Timor Baasov
Dana Atia-Glikin
Jeyakumar Kandasamy
Valery Belakhov
Original Assignee
Technion Research & Development Foundation Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technion Research & Development Foundation Ltd. filed Critical Technion Research & Development Foundation Ltd.
Publication of CY1120082T1 publication Critical patent/CY1120082T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B65CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65DCONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D79/00Kinds or details of packages, not otherwise provided for
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00Processes for the preparation of sugar derivatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20Carbocyclic rings
    • C07H15/22Cyclohexane rings, substituted by nitrogen atoms
    • C07H15/222Cyclohexane rings substituted by at least two nitrogen atoms
    • C07H15/226Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings
    • C07H15/228Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings attached to adjacent ring-carbon atoms of the cyclohexane rings
    • C07H15/23Cyclohexane rings substituted by at least two nitrogen atoms with at least two saccharide radicals directly attached to the cyclohexane rings attached to adjacent ring-carbon atoms of the cyclohexane rings with only two saccharide radicals in the molecule, e.g. ambutyrosin, butyrosin, xylostatin, ribostamycin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06Aminosugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Mechanical Engineering (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CY20181100039T 2010-11-18 2018-01-15 Αμινογλυκοσιδες και χρησεις αυτων στη θεραπευτικη αγωγη γενετικων διαταραχων CY1120082T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41495610P 2010-11-18 2010-11-18
PCT/IL2011/000889 WO2012066546A1 (en) 2010-11-18 2011-11-17 Aminoglycosides and uses thereof in treating genetic disorders

Publications (1)

Publication Number Publication Date
CY1120082T1 true CY1120082T1 (el) 2018-12-12

Family

ID=45390144

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100039T CY1120082T1 (el) 2010-11-18 2018-01-15 Αμινογλυκοσιδες και χρησεις αυτων στη θεραπευτικη αγωγη γενετικων διαταραχων

Country Status (18)

Country Link
US (7) US8895519B2 (enExample)
EP (2) EP3296311B1 (enExample)
JP (3) JP5960712B2 (enExample)
CA (1) CA2816789C (enExample)
CY (1) CY1120082T1 (enExample)
DK (1) DK2640734T3 (enExample)
ES (2) ES2655916T3 (enExample)
HR (1) HRP20180056T1 (enExample)
HU (1) HUE036248T2 (enExample)
IL (3) IL266495B (enExample)
LT (1) LT2640734T (enExample)
NO (1) NO2640734T3 (enExample)
PL (1) PL2640734T3 (enExample)
PT (1) PT2640734T (enExample)
RS (1) RS56739B1 (enExample)
SI (1) SI2640734T1 (enExample)
SM (1) SMT201800019T1 (enExample)
WO (1) WO2012066546A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE036248T2 (hu) 2010-11-18 2018-06-28 Technion Res & Dev Foundation Aminoglükozidok és alkalmazásaik genetikai rendellenességek kezelésére
KR101703137B1 (ko) 2014-05-30 2017-02-07 선문대학교 산학협력단 당 부가 아미노글리코사이드 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물
EP3151840A1 (en) * 2014-06-05 2017-04-12 Eloxx Pharmaceuticals Ltd. Use of aminoglycoside analogs in the treatment of rett syndrome
HK1257935A1 (zh) * 2015-09-02 2019-11-01 Eloxx Pharmaceuticals Ltd. 氨基糖苷衍生物及其在治疗遗传性病症中的应用
EP3344640A4 (en) * 2015-09-02 2019-05-01 Eloxx Pharmaceuticals Ltd. AMINO-LIKES DERIVATIVES AND USES THEREOF FOR THE TREATMENT OF GENETIC DISEASES
WO2017037718A1 (en) * 2015-09-02 2017-03-09 Eloxx Pharmaceuticals Ltd. Aminoglycoside derivatives and uses thereof in treating genetic disorders
WO2017118968A1 (en) * 2016-01-05 2017-07-13 Eloxx Pharmaceuticals Ltd. Aminoglycoside derivatives and uses thereof in treating genetic disorders
JP7187471B2 (ja) * 2017-03-15 2022-12-12 エロックス ファーマシューティカルズ リミテッド 擬似三糖アミノグリコシドおよびその中間体の大規模調製
WO2019237076A1 (en) * 2018-06-07 2019-12-12 Eloxx Pharmaceuticals, Inc. Methods, compositions, and kits for inducing readthrough
KR102067477B1 (ko) * 2018-06-20 2020-01-17 고려대학교 산학협력단 스킬로이노사민을 포함하는 아미노사이클리톨 화합물, 이의 제조방법 및 이를 함유하는 약학 조성물
WO2020113124A1 (en) * 2018-11-29 2020-06-04 Eloxx Pharmaceuticals Methods, compositions, and kits for treating ocular diseases
WO2021061873A1 (en) * 2019-09-23 2021-04-01 Eloxx Pharmaceuticals, Inc. Methods, compositions, and kits for treating polycystic kidney disease
EP4230196A1 (en) 2022-02-21 2023-08-23 Som Innovation Biotech, S.A. Compounds for use in the treatment of dystrophinopathies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5960712A (ja) 1982-09-30 1984-04-06 Toshiba Corp デ−タ判別装置
JP5830213B2 (ja) 2004-02-17 2015-12-09 ザ ホスピタル フォー シック チルドレン Mecp2e1遺伝子
LT2390255T (lt) * 2006-04-03 2016-10-25 Technion Research & Development Foundation Ltd. Nauji aminoglikozidai ir jų panaudojimas genetinių sutrikimų gydyme
HUE036248T2 (hu) * 2010-11-18 2018-06-28 Technion Res & Dev Foundation Aminoglükozidok és alkalmazásaik genetikai rendellenességek kezelésére
EP3151840A1 (en) * 2014-06-05 2017-04-12 Eloxx Pharmaceuticals Ltd. Use of aminoglycoside analogs in the treatment of rett syndrome

Also Published As

Publication number Publication date
WO2012066546A1 (en) 2012-05-24
US20190224226A9 (en) 2019-07-25
US9616079B2 (en) 2017-04-11
US20210228608A1 (en) 2021-07-29
NO2640734T3 (enExample) 2018-03-17
CA2816789A1 (en) 2012-05-24
SI2640734T1 (en) 2018-02-28
EP2640734A1 (en) 2013-09-25
US20170182078A1 (en) 2017-06-29
IL266495A (en) 2019-07-31
PT2640734T (pt) 2018-01-22
HUE036248T2 (hu) 2018-06-28
IL284067B (en) 2022-03-01
SMT201800019T1 (it) 2018-03-08
CA2816789C (en) 2018-12-11
IL284067A (en) 2021-07-29
ES2833938T3 (es) 2021-06-16
US11865128B2 (en) 2024-01-09
JP2018123135A (ja) 2018-08-09
HK1248709A1 (en) 2018-10-19
JP5960712B2 (ja) 2016-08-02
US9943533B2 (en) 2018-04-17
US9175029B2 (en) 2015-11-03
JP2016121168A (ja) 2016-07-07
US20180200276A1 (en) 2018-07-19
IL277063A (en) 2020-10-29
LT2640734T (lt) 2018-02-12
IL266495B (en) 2020-09-30
US20130237489A1 (en) 2013-09-12
JP6758338B2 (ja) 2020-09-23
DK2640734T3 (en) 2018-01-22
US10398718B2 (en) 2019-09-03
JP2013542981A (ja) 2013-11-28
PL2640734T3 (pl) 2018-04-30
US20140357590A1 (en) 2014-12-04
US20160074425A1 (en) 2016-03-17
EP2640734B1 (en) 2017-10-18
ES2655916T3 (es) 2018-02-22
HRP20180056T1 (hr) 2018-02-09
US20200078386A1 (en) 2020-03-12
EP3296311A1 (en) 2018-03-21
US10973839B2 (en) 2021-04-13
EP3296311B1 (en) 2020-09-30
IL277063B (en) 2021-07-29
US8895519B2 (en) 2014-11-25
RS56739B1 (sr) 2018-03-30

Similar Documents

Publication Publication Date Title
CY1120082T1 (el) Αμινογλυκοσιδες και χρησεις αυτων στη θεραπευτικη αγωγη γενετικων διαταραχων
CY1120073T1 (el) Παραγωγα πυραζολο-αμινοπυριμιδινης ως ρυθμιστες της lrrk2
ZA202409114B (en) MODULATORS OF THR-ß AND METHODS OF USE THEREOF
CU20210065A7 (es) Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibitoria en cdk2
CY1122703T1 (el) 1η-πυραζολο[3,4-β]πυριδινες και θεραπευτικες χρησεις αυτων
EA201291220A1 (ru) Производные аминопиримидина в качестве модуляторов lrrk2
CY1118129T1 (el) 5-αλκυνυλ-πυριμιδινες
MX2013000821A (es) Nuevas aminopirazoloquinazolinas.
EP4667495A3 (en) Bioactive molecule conjugate, preparation method and use thereof
CY1118771T1 (el) Μακροκυκλικα παραγωγα για την αγωγη υπερπλαστικων παθησεων
WO2018102452A3 (en) Using substituted pyrazole compounds for treatment of hyperproliferative diseases
WO2014205317A3 (en) Cyclic peptides as protein targeting agents
WO2012016186A8 (en) Macrocyclic kinase inhibitors and uses thereof
DOP2013000243A (es) Inhibidores sustituidos de acetil-coa carboxilasa
MX373042B (es) Moleculas para administracion a celulas cancerosas mutantes ros1.
AU2009258496A8 (en) Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity
MX380928B (es) Inhibidores de kras g12c.
MX384868B (es) Composiciones para tratar atrofia muscular espinal.
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
MX2014006027A (es) Derivados de 2-fenilaminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2) para el tratamiento de la enfermedad de parkinson.
HK1215579A1 (zh) 被取代的2,3-二氫苯並呋喃基化合物和其用途
IN2015DN01119A (enExample)
AU2018253590A1 (en) Imidazopyridazine compounds
EA201171087A1 (ru) СПОСОБЫ ВВЕДЕНИЯ (4aR,10aR)-1-н-ПРОПИЛ-1,2,3,4,4a,5,10,10a-ОКТАГИДРОБЕНЗО[g]ХИНОЛИН-6,7-ДИОЛА И РОДСТВЕННЫХ СОЕДИНЕНИЙ ЧЕРЕЗ СЛИЗИСТУЮ ОБОЛОЧКУ ПОЛОСТИ РТА, СЛИЗИСТУЮ ОБОЛОЧКУ НОСА ИЛИ КОЖУ И ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ НА ИХ ОСНОВЕ